Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump

In This Article:

Corcept Therapeutics (CORT) said Monday its phase 3 trial of relacorilant plus nab-paclitaxel to tre

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.